Literature DB >> 9315545

Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.

E G Daoud1, B P Knight, R Weiss, M Bahu, W Paladino, R Goyal, K C Man, S A Strickberger, F Morady.   

Abstract

BACKGROUND: Atrial fibrillation (AF) shortens the atrial effective refractory period (ERP) and predisposes to further episodes of AF. The purpose of this study was to determine the effect of verapamil and procainamide on these manifestations of AF-induced electrical remodeling. METHODS AND
RESULTS: In adult patients without structural heart disease, the atrial ERP was measured before and after AF after pharmacological autonomic blockade and administration of verapamil (17 patients), procainamide (10 patients), or saline (20 patients). AF was then induced by rapid pacing. Immediately on AF conversion, the post-AF ERP was measured at alternating drive cycle lengths of 350 and 500 ms. In the saline group, the pre-AF and first post-AF ERPs at the 350-ms drive cycle length were 206+/-19 and 179+/-27 ms (P<.0001), respectively, and at the 500-ms drive cycle length, the values were 217+/-16 and 183+/-23 ms, respectively (P<.0001). There was a similar significant shortening of the first post-AF ERP in the procainamide group. In the verapamil group, however, there was no difference between the pre-AF and the first post-AF ERP at the 350-ms (226+/-15 versus 227+/-22 ms, P=.8) or 500-ms (230+/-17 versus 232+/-20 ms, P=.6) drive cycle length. During determinations of the post-AF ERP, 105 secondary episodes of AF were unintentionally induced in 12% of verapamil patients compared with 90% and 80% of saline and procainamide patients (P<.01 versus verapamil).
CONCLUSIONS: Pretreatment with the calcium channel antagonist verapamil, but not the sodium channel antagonist procainamide, markedly attenuates acute, AF-induced changes in atrial electrophysiological properties. These data suggest that calcium loading during AF may be at least partially responsible for AF-induced electrical remodeling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315545     DOI: 10.1161/01.cir.96.5.1542

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

Review 1.  Novel catheter technology for ablative cure of atrial fibrillation.

Authors:  M D Lesh; P Guerra; F X Roithinger; Y Goseki; C Diederich; W H Nau; M Maguire; K Taylor
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study.

Authors:  E Bertaglia; D D'Este; A Zanocco; F Zerbo; P Pascotto
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

3.  Acute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholamines.

Authors:  A J Drake-Holland; M I Noble; M J Lab
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

Review 4.  Mechanisms underlying the development of atrial arrhythmias in heart failure.

Authors:  Vias Markides; Nicholas S Peters
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 5.  Catheter mapping of spontaneous and induced atrial fibrillation in man.

Authors:  S Saksena; A Shankar; A Prakash; R B Krol
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

6.  Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Ralf E Wessel; Sara Laszlo; Mathias C Busch; Jürgen Schreieck; Ralph F Bosch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-15       Impact factor: 3.000

7.  Influence of verapamil on tachycardia-induced alterations of PP1 and PP2A in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Sara Laszlo; Christian Eick; Jürgen Schreieck; Ralph F Bosch
Journal:  Exp Clin Cardiol       Date:  2007

Review 8.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 9.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

10.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.